FLINT, Mich., Oct. 10, 2017 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO), is now filling prescriptions for
newly approved VERZENIO™ (abemaciclib), a twice-daily oral therapy
for advanced breast cancer.
To learn more about Diplomat's oncology program, visit
diplomat.is/areas-of-excellence/oncology.
VERZENIO is indicated as a combination treatment with
FASLODEX® (fulvestrant) in women with hormone receptor
(HR)-positive, human epidermal growth factor receptor 2
(HER2)-negative advanced or metastatic breast cancer with disease
progression following endocrine therapy.
VERZENIO is also approved as a monotherapy for the treatment of
adult patients with HR-positive, HER2-negative advanced or
metastatic breast cancer with disease progression following
endocrine therapy and prior chemotherapy in the metastatic
setting.
"This therapy represents yet another step forward in the way the
health care community approaches treating advanced stages of this
disease. We are proud to support patients dealing with breast
cancer by dispensing VERZENIO," said Joel
Saban, Diplomat president.
According to the American Cancer Society, breast cancer is the
second most common cancer in American women, with more than 250,000
diagnoses expected in 2017.
VERZENIO is manufactured by Eli Lilly and Company. For full
prescribing information, click here.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended Dec. 31,
2016, and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) is the nation's largest independent
provider of specialty pharmacy services—helping patients and
providers in all 50 states. The company offers medication
management programs for people with complex chronic diseases and
delivers unique solutions for manufacturers, hospitals, payors,
providers, and more. Diplomat opened its doors in 1975 as a
neighborhood pharmacy with one essential tenet: "Take good care of
patients and the rest falls into place." Today, that tradition
continues—always focused on improving patient care and clinical
adherence. For more information, visit diplomat.is.
CONTACT:
Kali Lucas,
Public Relations Specialist
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is
View original content with
multimedia:http://www.prnewswire.com/news-releases/diplomat-selected-to-dispense-verzenio-for-breast-cancer-300533391.html
SOURCE Diplomat Pharmacy, Inc.